News

Canon Medical Systems USA Inc. Announces Expansion of Distributorship with the Acquisition of NXC Imaging

Tustin, California, (GLOBE NEWSWIRE) — Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation and a global leader in innovative diagnostic imaging technology, today announces it has signed a definitive agreement to acquire NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota. Founded in 1964, NXC Imaging’s distributorship area spans the U.S. Upper Midwest. The acquisition is expected to close in the third quarter of the 2022 calendar year.

The addition of NXC Imaging to Canon Medical Systems USA will strengthen its sales and service channels across the Upper Midwest in Canon’s diagnostic imaging portfolio that includes modalities of Computed Tomography (CT), Positron Emission Tomography (PET), Magnetic Resonance (MR), X-ray (XR), Vascular Imaging (VL) and Ultrasound (UL). Canon Medical plans to continue building its substantial sales and service organization, offering innovative solutions and unique business models tailored to each client’s specific needs.

“We have partnered with NXC Imaging for over 33 years,” said Yuji Hamada, CEO and President of Canon Medical Systems USA Inc. “Our successful partnership has thrived due to Canon’s innovative technology and trusting collaboration with NXC’s entrepreneurial company culture. The results of our partnership have demonstrated strong results over the past 15 years in the Upper Midwest region.”

“Our company’s foundation was built on our long-term customer relationships, trust, and loyalty in our territories. As a result, we have provided exceptional technology solutions and best-in-class support. We are proud of the legacy we’ve created and know that as a part of Canon Medical, we will continue to provide the Upper Midwest region with the same “Never Ordinary” customer service we are known for,” stated Bruce Zeilinger, President, and CEO of NXC Imaging.

Read more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and